␣ 2-M in pulmonary edema fluid; neutrophils; IL-8 receptors; specific binding ACUTE LUNG INJURY and acute respiratory distress syndrome (ALI/ARDS) are characterized by diffuse lung injury resulting in deterioration of lung function. Due to an increase in capillary-alveolar membrane permeability, ␣ 2 -macroglobulin (␣ 2 -M) translocates into the air spaces in patients with ALI/ARDS (30, 32) . ␣ 2 -M is a proteinase inhibitor that exists both in a "native" (or "slow") and modified (or "fast") form. This latter form of ␣ 2 -M migrates faster than native ␣ 2 -M during electrophoresis (9) . Slow (native) ␣ 2 -M displays anti-proteinase activity. The fast or inactive form of ␣ 2 -M is generated on the reaction with neutrophil elastase, a product of the neutrophils that accumulates in the alveolar space in patients with ALI/ARDS (29, 31) .
␣ 2 -M binds several cytokines, including interleukin-8 (IL-8) (12, 14, 17) . IL-8 is a potent neutrophil attractant and activator (23) . Several studies have demonstrated that high concentrations of IL-8 are present in bronchoalveolar lavage (BAL) and pulmonary edema fluids from patients with ALI/ARDS (5, 7, (18) (19) (20) . Furthermore, a significant fraction of IL-8 in BAL fluid is associated with ␣ 2 -M (14) . IL-8 binds only to fast (methylamine-treated) ␣ 2 -M. [Methylamine is routinely used to convert slow (native) ␣ 2 -M to fast form (9) .] In addition, in vitro both IL-8 and ␣ 2 -M/IL-8 complexes bind to specific receptors for IL-8 on human neutrophils with similar affinity (13) .
Most of ␣ 2 -M in BAL fluid of patients with ALI/ ARDS is associated with neutrophil elastase (fast form) (32) . Therefore, we hypothesized that lower levels of active ␣ 2 -M were present in pulmonary edema fluid of patients with ALI/ARDS than in patients with hydrostatic pulmonary edema. Because IL-8 binds to the inactive, fast form of ␣ 2 -M, we also hypothesized that the levels of ␣ 2 -M/IL-8 complexes would be increased in ALI/ARDS patients compared with control patients with hydrostatic pulmonary edema. Furthermore, we wanted to test the hypothesis that the IL-8 bound to ␣ 2 -M in pulmonary edema fluid of ALI/ARDS patients is biologically active. In contrast to our previous studies using BAL fluid from patients with ALI/ARDS and from healthy volunteers, we used undiluted pulmonary edema fluid in this study because pulmonary edema fluid reflects the actual lung environment more accurately than BAL fluid. Because BAL fluids from individual patients are diluted, interpretation of the data is also somewhat difficult. In addition, we compared the interaction between IL-8 and ␣ 2 -M in pulmonary edema fluids from patients with ALI/ARDS and from patients with hydrostatic edema, an ideal group of control patients who are ventilated and critically ill but have pulmonary edema primarily due to elevated pul-monary vascular pressure (28) . Furthermore, because of a sustained inflammatory response in the latter group, no significant increase in concentrations of IL-8 and ␣ 2 -M is expected (25, 28) .
MATERIALS AND METHODS
Human subjects. All studies involving human blood and pulmonary edema fluid were approved by the Human Subjects Investigation Committees of the University of California, San Francisco, and the University of Texas Health Center at Tyler. Informed written consent was obtained from all the subjects or their representatives. ALI was diagnosed according to the following criteria: 1) PaO 2 -to-FIO 2 ratio Յ300 mmHg, 2) bilateral infiltrates on the chest radiograph, and 3) a pulmonary artery wedge pressure of Յ18 mmHg and/or no clinical evidence of elevated left atrial pressure (1) . Hydrostatic pulmonary edema was defined as published before (28) . As in our prior studies (28) , the definition of hydrostatic edema was based on clinical evidence of cardiac dysfunction from an acute myocardial infarction, exacerbation of chronic heart failure, or volume overload with either a pulmonary arterial wedge pressure Ͼ18 mmHg or a two-dimensional echocardiogram demonstrating a reduction in the left ventricular ejection fraction plus the presence of a transudative pulmonary edema fluid-to-plasma total protein ratio Ͻ0.65. Pulmonary edema fluid samples from patients with ALI/ ARDS or hydrostatic pulmonary edema were obtained as previously described (30) . Briefly, pulmonary edema fluid samples were obtained within 15 min of intubation and mechanical ventilation. A 14-French suction catheter (Becton-Dickinson, Lincoln Park, NJ) was passed through the endotracheal tube and wedged into the distal airways. Then, edema fluid samples were suctioned gently through the inserted catheter. The samples were centrifuged at 3,000 g for 10 min, and the supernatants were stored at Ϫ70°C until use.
Measurement of total protein. The total protein concentration in the edema fluid samples was measured by using Coomassie Plus protein assay reagent (Pierce, Rockford, IL) according to the manufacturer's instructions. For the measurement of edema fluid-to-plasma protein concentration ratios, protein concentration was measured by the biuret method as previously described (28) .
Measurement of concentration of ␣2-M. The concentration of ␣2-M in the edema fluid samples was measured in an ELISA assay as previously described (2, 14) .
Visualization of different forms of ␣2-M in the edema fluid samples (electrophoresis I). To establish the state of ␣2-M (slow vs. fast), pulmonary edema fluid samples were subjected to nondenaturing polyacrylamide gel electrophoresis (5% Tris-borate). The gels were then stained with Coomassie blue.
Measurement of slow/native ␣2-M (trypsin binding assay). To calculate the amount of slow or native form, ␣2-M was tested for trypsin binding activity by the method of Ganrot (8) . The activity of trypsin (Sigma, St. Louis, MO) was determined by active site titration with the substrate, p-nitrophenyl-pЈ-guanidinobenzoate hydrochloride (4) .
Measurement of the quantity of ␣2-M bound to neutrophil elastase (␣2-M/elastase complexes) in the edema fluid samples. The concentration of neutrophil elastase bound to ␣2-M in pulmonary edema fluid was determined by measuring the rate of hydrolysis of the elastase substrate MeOSuc-Ala-AlaPro-Val-NH-Np in the presence and absence of an ␣ 1-proteinase inhibitor (a generous gift from Dr. Hall James, the University of Texas Health Center, Tyler, TX) (21) .
Measurement of concentration of IL-8. IL-8 concentration in the edema fluid samples was measured in an ELISA assay developed in our laboratory by using a matched antibody pair according to the manufacturer's protocol (R&D Systems, Minneapolis, MN).
Measurement of concentration of ␣2-M/IL-8 complexes. The concentration of ␣2-M/IL-8 complexes in the edema fluid samples was measured by using a specific ELISA assay developed in our laboratory (14) .
Visualization of binding of 125 I-recombinant human IL-8 to ␣2-M in the edema fluid samples (electrophoresis II).
Recombinant human IL-8 (rhIL-8; R&D Systems) was labeled with 125 I (11). Pulmonary edema fluid samples were incubated with labeled IL-8, and complexes of 125 I-rhIL-8 with ␣2-M were detected by nondenaturing polyacrylamide gel electrophoresis (5% Tris-borate) and autoradiography (22) . In this type of electrophoresis only ␣ 2-M bands can be detected using Coomassie blue stain (see Fig. 1 ). When samples are incubated with 125 I-rhIL-8, radioactive bands are visualized by autoradiography. These bands represent 125 I-rhIL-8 bound to ␣2-M and migrate as does ␣2-M alone.
Purification of ␣2-M/IL-8 complexes (gel filtration chromatography).
To purify ␣2-M/IL-8 complexes, we separated the pulmonary edema fluid samples on an HPLC gel filtration column, TSK-250. PBS was used as elution buffer at a flow rate of 0.25 ml/min, and the fractions were analyzed using IL-8 ELISA.
Preparation of neutrophils. Human neutrophils from healthy volunteers were separated by dextran sedimentation and erythrocyte lysis by the method of Boyum (3). The purity of neutrophils was usually 80-90%.
Competition between purified ␣2-M/IL-8 complexes and 125 I-labeled rhIL-8 for binding to IL-8 receptors on neutrophils (binding studies).
Binding studies were performed utilizing neutrophils suspended in PBS containing 1% BSA. The cells (1 ϫ 10 6 ) were incubated with 125 I-labeled rhIL-8 in the presence or absence of different concentrations of unlabeled rhIL-8 or purified ␣ 2-M/IL-8 complexes for 90 min at 4°C to reach equilibrium and then centrifuged. The pellet ("bound" counts) and supernatant ("free" counts) were counted in a gamma radiation spectrometer (14) . In some experiments, we treated the samples with human neutrophil elastase (Elastin Products, Owensville, MO) or incubated with goat anti-human ␣ 2-M IgG (ICN Pharmaceuticals, Costa Mesa, CA) before adding 125 I-labeled rhIL-8.
Measurement of activity of purified ␣2-M/IL-8 complexes (neutrophil chemotaxis).
Chemotactic activity of neutrophils (0.4 ϫ 10 6 /chemotactic chamber) was assessed by the leading front method of Zigmond and Hirsch as previously described (14, 33) .
Binding of IL-8 to elastase-treated commercial ␣2-M. ␣2-M (10 g) obtained from Biodesign International (Kennebunk, ME) was incubated with human neutrophil elastase (Elastin Products) and 125 I-labeled rhIL-8 for 0, 1.5, 3, 6, and 24 h in the presence or absence of the elastase inhibitor phenylmethylsulfonyl fluoride (Sigma). The samples were electrophoresed on a native 5% gel. Gels were then dried for autoradiography, and the autoradiographs were scanned.
Affinity of IL-8 binding to elastase-treated commercial ␣2-M. Different concentrations of elastase-treated ␣2-M were incubated with rhIL-8 overnight at 25°C. The samples were electrophoresed on native 5% gels or SDS-polyacrylamide 4-20% gradient gels. Gels were dried and subjected to autoradiography. In addition, to estimate the amount of IL-8 bound to ␣ 2-M, autoradiographs of the gels were scanned. The dissociation constant (Kd) was calculated as previously described (14) . Briefly, the amount of noncovalently bound IL-8 was calculated by subtracting the amount of IL-8 detected in SDS-electrophoresis from the amount detected in native gel electrophoresis. Furthermore, the K d for noncovalent binding can be expressed as: I/MI ϭ Kd(1/M), where M is ␣2-M, I is IL-8, and MI is a reversible (noncovalent) ␣2-M/ IL-8 complex.
Activity of IL-8 bound to elastase-treated commercial ␣2-M (neutrophil enzyme release). The assay was performed in a 96-well plate, and 0.6 ϫ 10 6 cells were added to each well. Myeloperoxidase was measured by determining the change in absorbance of tetramethyl benzidine (Sigma) at 450 nm in the presence of hydrogen peroxide as previously described (26) . N-formylmethionyl-leucyl-phenylalanine (Sigma) was used as a positive control.
Statistical analysis. Comparisons between groups were done using the Student's t-test or the nonparametric MannWhitney rank sum test when the data sets were not normally distributed and Fisher's exact test. Results are presented as means Ϯ SD. All statistics were performed using SIGMA-STAT (SPSS Science, Chicago, IL).
RESULTS
Patients with ALI/ARDS and hydrostatic pulmonary edema. Nineteen patients with ALI/ARDS and seven patients with hydrostatic pulmonary edema were included in this study. The characteristics of the two patient groups are outlined in Table 1 . The mean severity of illness (simplified acute physiology score) and the lung injury score were similar for the two groups. This has been a common finding in many of our studies (27) . In addition, there was a higher incidence of sepsis and renal failure in the ALI/ARDS patients (Table 1) .
Edema fluid/plasma protein concentration ratio. The edema fluid-to-plasma protein concentration ratio was significantly higher in patients with ALI/ARDS compared with patients with hydrostatic edema (0.98 Ϯ 0.21 and 0.63 Ϯ 0.28) (P Ͻ 0.01). The total protein concentration in the edema fluid was also increased in ALI/ARDS patients compared with patients with hydrostatic edema (4.7 Ϯ 1.6 and 3.0 Ϯ 0.6 g/100 ml, respectively) (P Ͻ 0.05). (Fig. 2A) due to the increase in capillary-alveolar permeability. As hypothesized, due to differences in the nature of pulmonary inflammation, the relative amount of slow or native ␣ 2 -M (expressed as a percentage of total ␣ 2 -M) was decreased in patients with ALI/ARDS. Pulmonary edema fluid from patients with ALI/ARDS contained significantly less slow or native ␣ 2 -M (expressed as a percentage of total ␣ 2 -M) than did pulmonary edema fluid from hydrostatic edema patients (P Ͻ 0.001) (Fig. 2B) . In addition, the quantity of ␣ 2 -M bound to neutrophil elastase or fast ␣ 2 -M (expressed as a percentage of total ␣ 2 -M) was higher in patients with ALI/ARDS compared with patients with hydrostatic edema (34 Ϯ 33% vs. 8 Ϯ 19%), though that difference did not quite reach statistical significance (P ϭ 0.06). Because the total ␣ 2 -M concentration was significantly higher in patients with ALI/ARDS, the actual concentration of the slow form did not differ between patient groups (0.33 Ϯ 0.19 and 0.31 Ϯ 0.20 mg/ml, for ALI/ARDS and hydrostatic edema groups, respectively) (P ϭ 0.83). However, the concentration of ␣ 2 -M bound to neutrophil elastase was significantly increased in patients with ALI/ARDS compared with patients with hydrostatic edema (0.28 Ϯ 0.29 and 0.03 Ϯ 0.06 mg/ml, respectively) (P Ͻ 0.05).
Interaction of IL-8 with ␣ 2 -M. The pulmonary edema fluid concentrations of IL-8 were not significantly different between the two groups of patients (P ϭ 0.15), although in patients with ALI/ARDS, levels of IL-8 showed a tendency to increase (39 Ϯ 38 and 17 Ϯ 22 ng/ml, respectively). However, the concentration of ␣ 2 -M/IL-8 complexes was significantly higher in pulmonary edema fluid from patients with ALI/ARDS (P Ͻ 0.05) (Fig. 3) . Similarly, comparison of the ratios of Values are mean Ϯ SD. ALI/ARDS, Acute lung injury; SAPS, simplified acute physiology score; LIS, lung injury score. * P Ͻ 0.05. ␣ 2 -M/IL-8 complex concentrations to total protein concentrations using Fisher's exact test (␣ 2 -M/IL-8 complexes:total protein Ͼ 1.10 ng/mg) showed that patients with ALI/ARDS (18:1) significantly differed from patients with hydrostatic pulmonary edema (4:3) (P Ͻ 0.05). The mean ratio was 0.81 Ϯ 0.26 and 2.06 Ϯ 0.60 ng/mg for patients with ALI/ARDS and for patients with hydrostatic pulmonary edema, respectively.
In addition, edema fluid samples containing fast ␣ 2 -M were capable of binding 125 I-labeled rhIL-8. Samples containing slow ␣ 2 -M bound IL-8 after they were treated with methylamine (conversion of slow form to fast form). [Slow ␣ 2 -M does not bind IL-8 (14) .] For example, the first two samples that were run on the gel presented in Fig. 1 did not bind 125 I-labeled rhIL-8 without prior methylamine treatment, whereas the third sample did. We observed a similar phenomenon in our previous studies, except that plasma or commercial ␣ 2 -M were examined before (13, 14) .
Moreover, IL-8 that was present in ␣ 2 -M/IL-8 complexes, purified from edema fluids, retained its biological activity as shown by binding to IL-8 receptors on neutrophils. ␣ 2 -M/IL-8 complexes competed with 125 Ilabeled rhIL-8 to bind to IL-8 receptors (Fig. 4) . The typical inhibition curve was obtained when different concentrations of purified complexes were incubated with 125 I-labeled rhIL-8 and the cells (Fig. 4) (14) . This suggests that IL-8 in purified complexes bound to IL-8 receptors on neutrophils. [␣ 2 -M does not bind to neutrophils (13) .] In addition, the neutralizing antibody against ␣ 2 -M substantially decreased the ability of ␣ 2 -M/IL-8 complexes to compete with 125 I-labeled rhIL-8 to bind to receptors on neutrophils (P Ͻ 0.01) (Fig. 4) . The two inhibition curves were compared with Fig. 2 . ␣2-M in pulmonary edema fluids from patients with ALI/ ARDS and hydrostatic pulmonary edema. A: total ␣2-M concentration in pulmonary edema fluids from patients with ALI/ARDS and hydrostatic pulmonary edema (P Ͻ 0.01). B: slow ␣2-M in pulmonary edema fluids from patients with ALI/ARDS and hydrostatic pulmonary edema (*P Ͻ 0.001). (14) and suppresses their binding to IL-8 receptors on neutrophils. Complexed IL-8 was also protected from proteolytic degradation (␣ 2 -M/IL-8 complexes treated with elastase displayed similar activity to untreated complexes in the competition assay) (P Ͼ 0.05). Furthermore, the neutrophil chemotactic activity of the complexes (80 Ϯ 7%) was similar to that of IL-8 alone suspended in buffer (100%) (P Ͼ 0.05).
Interaction of IL-8 with elastase-modified ␣ 2 -M in vitro. Because purified ␣ 2 -M/IL-8 complexes contained elastase (bound to ␣ 2 -M), we studied the interaction of IL-8 with ␣ 2 -M, which was treated with elastase in vitro. IL-8 bound to elastase-modified ␣ 2 -M in a saturable manner, and the calculated K d was ϳ6 ϫ 10 Ϫ8 M. We also examined the effect of IL-8 in complex with elastase-modified human ␣ 2 -M on the release of myeloperoxidase, a marker of neutrophil activation (Fig. 5) . The complexed IL-8 did not differ from free IL-8 in its ability to release myeloperoxidase from human neutrophils (P Ͼ 0.05). In addition, ␣ 2 -M alone did not exhibit any activity (Fig. 5) .
DISCUSSION
The major findings of this study can be summarized as follows. In patients with ALI/ARDS, the quantity of ␣ 2 -M complexed with elastase in pulmonary edema fluid was increased, and consequently the quantity of slow (native) ␣ 2 -M was decreased. There was a corresponding increase in the quantity of fast ␣ 2 -M in pulmonary edema fluid from patients with ALI/ARDS. The increase in the fast form of ␣ 2 -M may result in increased binding to proinflammatory cytokines. Accordingly, as we hypothesized, there was a significant increase in ␣ 2 -M/IL-8 complexes in pulmonary edema fluid from patients with ALI/ARDS compared with control patients with hydrostatic edema. In addition, the results indicate that IL-8 complexed to ␣ 2 -M remains biologically active. This is the first study to describe the function of IL-8 complexed to ␣ 2 -M in pulmonary edema fluid. In addition, this is the first study to define the activity of IL-8 in ␣ 2 -M/IL-8 complexes purified from pulmonary edema fluid. Thus our observations are more closely related to in vivo conditions than our prior studies of the in vitro activity of IL-8 (13) (14) (15) .
An important feature of ALI/ARDS is that large proteins, such as ␣ 2 -M, translocate across the injured endothelial and epithelial barriers of the lung and accumulate in the air spaces (10, 29) . Wewers et al. (32) showed that the majority (70%) of ␣ 2 -M present in BAL fluid from patients with ALI/ARDS is complexed to neutrophil elastase. However, only 34% of the total ␣ 2 -M was complexed with neutrophil elastase in our study. The difference between the studies may be due to the fact that the former used BAL fluid whereas our study used pulmonary edema fluid. Furthermore, elastase complexed to ␣ 2 -M retains its enzymatic activity. This form of elastase was present in samples from five of seven patients with ALI/ARDS but only in one of 13 normal volunteers (32) . In our study, neutrophil elastase complexed with ␣ 2 -M was detected in 13 of the 19 patients with ALI/ARDS. Thus a similar number of patients with ALI/ARDS had the complexed elastase (70 vs. 68%, respectively) in both studies.
The intensity and character of inflammation are quite different in patients with ALI/ARDS and patients with hydrostatic pulmonary edema (24) . Accordingly, more patients with ALI/ARDS than with hydrostatic edema had elastase bound to ␣ 2 -M (13 in 19 patients and 2 in 7 patients, respectively). In addition, 34% of the total ␣ 2 -M was complexed with neutrophil elastase in patients with ALI/ARDS whereas only 8% was complexed in patients with hydrostatic edema. The concentration of ␣ 2 -M associated with elastase was significantly higher in these patients (P Ͻ 0.05). Furthermore, the activity of ␣ 2 -M (the ability to inhibit trypsin) ranged from 47% (%total) for ALI/ARDS to 85% (%total) for the hydrostatic edema group. However, because of the increased permeability to protein in patients with ALI/ARDS, the total amount of active ␣ 2 -M was similar in both groups of patients. The remaining ␣ 2 -M (not active or complexed with elastase) could be bound to other proteinases or modified by oxidation (25) .
In agreement with our previous study (14) , only a small fraction of the total ␣ 2 -M was associated with IL-8 (Ͻ1%). However, fast ␣ 2 -M present in pulmonary edema fluid was still able to bind IL-8. Accordingly, we found that the extent of 125 I-labeled rhIL-8 binding to pulmonary edema fluid ␣ 2 -M depended on the ␣ 2 -M state (slow vs. fast). Edema fluid samples that contained mostly native ␣ 2 -M bound 125 I-rhIL-8 only after treatment with methylamine (IL-8 does not bind to the slow form) (14) . Furthermore, the concentration of the ␣ 2 -M/IL-8 complexes was higher in patients with ALI/ ARDS than in patients with hydrostatic edema (P Ͻ 0.05). To determine whether the differences in ␣ 2 -M/ IL-8 complex concentrations were due to augmented intra-alveolar production of ␣ 2 -M versus translocation from the intravascular to the intra-alveolar compartment, we also examined the ␣ 2 -M/IL-8 complex concentration-to-total protein concentration ratios. The difference between ALI/ARDS and hydrostatic groups was still significant (P Ͻ 0.05).
Because ␣ 2 -M complexed to IL-8 was associated with elastase, the interaction between IL-8 and elastasetreated ␣ 2 -M was also studied in vitro. We found for the first time that IL-8 bound to elastase-modified ␣ 2 -M in a saturable manner in vitro, and the binding was of high affinity compared with other cytokines (6). The calculated K d was ϳ6 ϫ 10 Ϫ8 M. In addition, IL-8 in complex with elastase-modified ␣ 2 -M retained its biological activity.
IL-8 is an important neutrophil chemoattractant in lung fluids from patients with ALI/ARDS (19, 20) . Several studies have indicated the potential use of IL-8 as a marker of the development or outcome of ALI/ ARDS (5, 7, (18) (19) (20) . However, some ELISA assays do not recognize IL-8 that is bound to ␣ 2 -M (14) . The results of this study demonstrate that the IL-8 concentration in pulmonary edema fluid is at least two to three times higher that that measured by ELISA assay. Furthermore, purified ␣ 2 -M/IL-8 complexes displayed unchanged biological activity (chemotactic activity). Also, IL-8 complexed to ␣ 2 -M was protected from proteolytic degradation. Therefore, when the appearance of ␣ 2 -M/IL-8 complexes coincides with the influx of neutrophils, it may create a favorable environment for further neutrophil accumulation. This may explain why, in patients at risk for ALI/ARDS who subsequently developed ALI/ARDS, ␣ 2 -M/IL-8 complexes and neutrophil concentrations were correlated (P Ͻ 0.05; r 2 ϭ 1.00) (16) . On the other hand, our previous findings suggested that ␣ 2 -M could be an important mediator of IL-8 clearance (13, 15) . Those studies indicated that alveolar macrophages have receptors for ␣ 2 -M but not for IL-8. In addition, we found that complexes between rhIL-8 and fast human ␣ 2 -M are cleared by human alveolar macrophages via ␣ 2 -M receptors (13) . Furthermore, the instillation of IL-8 bound to the fast rabbit ␣-macroglobulin to the rabbit lung abolished the influx of neutrophils induced by the instillation of the same concentration of IL-8 alone (15) . These findings suggested that formation of ␣ 2 -M/IL-8 complexes facilitates clearance of IL-8. Accordingly, we found that the concentration of these complexes declined over time (between days 1 and 7 of ALI/ARDS) but interestingly only in ALI/ARDS survivors. This finding was independent of the decline in total protein concentration (14, 16) . Thus the data in this study, coupled with our earlier work, indicate that ␣ 2 -M/IL-8 complexes may modulate the acute inflammation in patients with ALI/ ARDS since ␣ 2 -M may affect degradation and clearance of proinflammatory IL-8. On the other hand, if availability of ␣ 2 -M receptors on macrophages is decreased, then ␣ 2 -M/IL-8 complexes could enhance the inflammatory process in the lung further by triggering the activation of neutrophils.
In summary, IL-8 in complex with ␣ 2 -M retains its biological activity. The complexes thus bind to IL-8 receptors on neutrophils. The complexes are also cleared by alveolar macrophages (via ␣ 2 -M receptors). Therefore, the fate of these complexes depends on the immediate environment surrounding them, e.g., cell type and the availability of receptors.
